Bioventus Inc. / Fundamentals
Income statement
- Net revenue
€484.03M - Cost of goods sold
€156.83M - Gross profit
€325.68M - SG&A expenses
€274.83M - R&D expenses
€11.36M - EBITDA
€72.43M - D&A
€41.69M - EBIT
€30.29M - Interest expenses
€28.77M - EBT
€1.97M - Tax expenses
€1.79M - Net income
-€135.56K
Cash flow statement
- Net deferred tax
€2.39M - Non-cash items
€6.19M - Changes in working capital
-€26.75M - Operating cash flow
€31.10M - Capex
€1.84M - Other investing cash flow
€19.98M - Net investing cash flow
€18.74M - Total cash dividends paid
€0.00 - Issuance of common stock
€2.68M - Debt repayment
-€37.12M - Other financing cash flow
-€13.79M - Net financing cash flow
-€48.23M - Foreign exchange effects
-€827.97K - Net change in cash
€785.93K - Cash at end of period
€28.24M - Free cash flow
€32.94M
Balance sheet
- Cash and cash equivalents
€28.24M - Cash and short-term investments
€28.24M - Total receivables
€113.57M - Inventory
€82.77M - Other current assets
€11.55M - Total current assets
€236.12M - Property, plant & equipment
€26.37M - Goodwill
€6.40M - Intangible assets
€332.01M - Long-term investments
€0.00 - Other non-current assets
€1.45M - Total non-current assets
€370.30M - Total assets
€606.42M - Accounts payable
€20.80M - Short-term debt
€37.20M - Other current liabilities
€97.33M - Total current liabilities
€159.31M - Long-term debt
€255.58M - Deferred tax liabilities
€558.56K - Other non-current liabilities
€18.26M - Total non-current liabilities
€274.40M - Total liabilities
€433.71M - Common stock
€71.21K - Retained earnings
-€302.74M - Other equity
-€664.09K - Total equity
€172.71M - Total liabilities and shareholders' equity
€606.42M
Company information
- Market capitalization
€383.18M - Employees
930 - Enterprise Value
€768.39M
Company ratios
- Gross margin
-
67.3% Much better than peer group: -109.5% - EBITDA margin
-
15.0% Much better than peer group: -30,606.1% - EBIT margin
-
6.3% Much better than peer group: -30,716.4% - EBT margin
-
0.4% Much better than peer group: -30,729.5% - Net margin
-
-0.0% Much better than peer group: -30,691.1% - ROE
-
-0.1% Much better than peer group: -240.6% - ROA
-
-0.0% Much better than peer group: -14,288.3% - Asset turnover
-
79.8% Much better than peer group: 25.5% - FCF margin
-
6.0% Much better than peer group: -22,967.0% - FCF yield
7.6% - Efficiency ratio
85.0% - Net sales per employee
-
€520.47K - Net income per employee
-
-€145.77